Welcome to our dedicated page for Cocrystal Pharma SEC filings (Ticker: COCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cocrystal Pharma, Inc. filings document material-event disclosures for a clinical-stage antiviral drug developer. Recent 8-K reports furnish press releases on CDI-988, including norovirus program updates, FDA Fast Track designation, scientific conference presentations and annual financial results tied to the antiviral pipeline.
The company’s filings also record Nasdaq Capital Market status, board and executive compensation matters under the 2025 Equity Incentive Plan, stock-option grants and director changes, along with Regulation FD disclosures and exhibits related to clinical and business updates.
Cocrystal Pharma (COCP) reported Q3 2025 results showing a net loss of $2.049 million and operating expenses of $2.089 million, reflecting sharp year‑over‑year cost reductions. For the nine months, net loss was $6.405 million as R&D spending eased following completion of a Phase 2a influenza study and Phase 1 norovirus/coronavirus trial work.
Liquidity remains tight. Cash and restricted cash were $7.804 million as of September 30, 2025, after using $6.456 million in operating cash year‑to‑date. Management stated there is “substantial doubt” about continuing as a going concern. To bolster funds, the company raised net $4.183 million in a September 12, 2025 registered direct offering (with concurrent private warrants) and $154,000 via ATM sales. Subsequent to quarter end, insiders purchased 739,426 units for gross proceeds of $1.03 million on October 28, 2025.
Pipeline updates: Oral CC‑42344 for influenza A completed Phase 2a with favorable safety. CDI‑988 completed Phase 1 with tolerability across doses up to 1,200 mg; the FDA cleared a Phase 1b norovirus challenge study, expected to begin in the first half of 2026. The company also reported a $500,000 NIH/NIAID SBIR Phase I award.
Cocrystal Pharma (COCP) reported insider activity by Phillip Frost, M.D., a director and 10% owner, on 10/28/2025. He acquired 359,713 shares of common stock at $1.39 per unit, with each unit also including a warrant to purchase two shares. He also acquired 719,426 warrants with a $1.24 exercise price, which were exercisable upon issuance and expire on 01/28/2028. The transaction was approved by a Special Committee under Rule 16b-3.
Following these transactions, Frost beneficially owned 1,679,551 shares indirectly through Frost Gamma Investments Trust, and 27,100 shares directly, which include shares issuable upon vesting of restricted stock units.
Cocrystal Pharma (COCP): director-affiliated entity reports purchase
Caret Group, LLC, a director of Cocrystal Pharma, reported buying 359,713 shares at $1.39 per unit on 10/28/2025. Each unit included one share and a warrant to purchase two shares. The filing shows 719,426 warrants acquired with a $1.24 exercise price, exercisable upon issuance and expiring on 01/28/2028.
Following the transaction, the reporting person beneficially owned 1,383,009 shares. This total includes shares issuable upon vesting of restricted stock units, as noted in the filing’s footnote.
Cocrystal Pharma (COCP) director Richard Pfenniger reported a purchase on 10/28/2025. He acquired 20,000 shares of common stock as part of units priced at $1.39 per unit, with each unit consisting of one share and a warrant to buy two shares. He also acquired 40,000 warrants with an exercise price of $1.24 and an expiration of 01/28/2028; the warrants were exercisable upon issuance.
Following the transactions, he beneficially owned 31,400 shares directly, which includes shares issuable upon vesting of restricted stock units. The purchase was approved by a Special Committee of the Board under Rule 16b-3.
Cocrystal Pharma (COCP) reported an insider purchase by a senior officer. On 10/28/2025, the reporting person acquired 3,598 shares of common stock at $1.39 per unit, with each unit also including warrants to buy two shares. The filing also shows acquisition of 7,196 warrants with a $1.24 exercise price, exercisable upon issuance and expiring on 01/28/2028. Following the transactions, beneficial ownership stands at 44,167 shares held directly, which includes shares issuable upon vesting of restricted stock units.
Cocrystal Pharma entered a private placement with four accredited insiders, selling 739,426 units at $1.39 per unit. Each unit includes one common share and a warrant to buy two shares at $1.24 per share for 27 months. The transaction generated $1.03 million in gross proceeds.
The sale was conducted at-the-market under Nasdaq rules and carried no registration rights. The offering relied on Section 4(a)(2) and Rule 506(b) exemptions. If fully exercised, the warrants would be exercisable for 1,478,852 additional shares.
Cocrystal Pharma (COCP) filed an 8-K stating it announced receipt of a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID). The announcement was made on October 27, 2025.
The company furnished a press release as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The company states this information is furnished and not deemed “filed” under Section 18 of the Exchange Act, and it is not incorporated by reference into other filings. Cocrystal’s common stock trades on the Nasdaq Capital Market under the symbol COCP.
Cocrystal Pharma, Inc. filed an S-1 registration statement to register shares held by selling stockholders under the Nasdaq symbol COCP. The prospectus states the selling stockholders may sell their shares at fixed, market-related or negotiated prices through various methods, and the company will not receive proceeds from those sales except to the extent of any cash exercises of the Warrants. The filing references standard risk disclosures warning that purchasers may lose their entire investment. Named selling stockholders include Orca Capital AG and L1 Capital Global Opportunities Master Fund, Ltd. The filing also lists estimated offering-related fees: legal $10,000, accounting $5,000 and a total of $15,702.38. The document includes officer and director signatures.
Cocrystal Pharma, Inc. filed an S-1 registration statement to register shares held by selling stockholders under the Nasdaq symbol COCP. The prospectus states the selling stockholders may sell their shares at fixed, market-related or negotiated prices through various methods, and the company will not receive proceeds from those sales except to the extent of any cash exercises of the Warrants. The filing references standard risk disclosures warning that purchasers may lose their entire investment. Named selling stockholders include Orca Capital AG and L1 Capital Global Opportunities Master Fund, Ltd. The filing also lists estimated offering-related fees: legal $10,000, accounting $5,000 and a total of $15,702.38. The document includes officer and director signatures.
Cocrystal Pharma, Inc. entered into a securities purchase agreement for a registered direct stock offering and concurrent private placement of warrants. The company agreed to sell 2,764,710 common shares at $1.70 per share and issue Investor Warrants to purchase up to 5,529,420 additional shares at an initial exercise price of $1.50 per share. The transaction closed with gross proceeds of approximately $4.75 million before fees, with net proceeds intended for general corporate purposes and development of antiviral medicines. Investor Warrants are exercisable immediately, subject to 4.99% or, at the holder’s election, 9.99% beneficial ownership limits, and expire 24 months after effectiveness of a resale registration statement the company must file by October 10, 2025.
Cocrystal Pharma, Inc. (COCP) is a clinical-stage antiviral biopharmaceutical company developing candidates for influenza, norovirus, coronavirus and HCV. The company reported a six-month net loss of $4.36 million and used $5.09 million of cash in operations through June 30, 2025. Cash and restricted cash totaled $4.84 million, total assets were $8.51 million and stockholders' equity was $5.33 million as of June 30, 2025. The company recorded a large accumulated deficit of $337.8 million (in thousands).
The filing discloses substantial doubt about the company’s ability to continue as a going concern and states current resources are not expected to be sufficient to fund operations beyond the next 12 months without additional financing. Clinical updates show MHRA authorization and ongoing analysis for the CC-42344 Phase 2a human challenge study and Phase 1 data for CDI-988 with safety/tolerability reported up to 1,200 mg. The company continues to rely on equity offerings and its ATM program for liquidity.